Laquinimod is an orally-available. quinolinone-based, broad spectrum immunomodulator with anti-inflammatory activity, most likely by effecting a T-helper cell 1 to 2 cytokine shift. [1] Additionally it reduces antigen presentation and the effect on migration of T-cells. Laquinimod is also believed to provide a neuroprotective effect and may have application to relapsing-remitting multiple sclerosis (RRMS). [2]

In animal models for multiple sclerosis, Laquinimod reversed established relapsing remitting experimental autoimmune encephalomyelitis (RR EAE) and was associated with reduced CNS inflammation, decreased Th1 and Th17 responses, and an increase in regulatory T cells. [3]